CCR2 and neoplasm: Peripheral blood was collected from RT-treated tumor-bearing (RT-TB) mice and non-RT-treated tumor-bearing (NT-TB) mice and the number of circulating IM (CD45+, CD11b+, Ly6C(high), Ly6G-, CCR2+) was determined by multicolor flow cytometry.